Trial Profile
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Bleomycin (Primary) ; Brentuximab vedotin (Primary) ; Cyclophosphamide (Primary) ; Dacarbazine (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Prednisone (Primary) ; Vinblastine (Primary) ; Vincristine (Primary) ; Filgrastim; Filgrastim
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 08 Feb 2022 Planned number of patients changed from 200 to 250.
- 11 Dec 2018 Status changed from not yet recruiting to recruiting.
- 06 Dec 2018 New trial record